Related Experiment Videos
[New combination therapies in hematological malignancies]
1Department of Internal Medicine III, Hamamatsu University School of Medicine, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 31, 2000
Summary
New combination therapies show promise for hematological malignancies. Anti-CD20 antibodies benefit indolent B cell lymphoma, while multidrug resistance modifiers aid AML treatment.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Hematological malignancies require novel therapeutic strategies.
- Standard treatments can be limited by resistance and relapse.
- Combination therapies are emerging as a promising approach.
Purpose of the Study:
- To review recent advances in combination therapies for hematological malignancies.
- To evaluate the efficacy and toxicity of novel treatment regimens.
- To identify effective strategies for overcoming drug resistance and preventing relapse.
Main Methods:
- Review of recent clinical studies and case reports.
- Analysis of combination therapies including anti-CD20 antibodies, multidrug resistance modifiers, and chemotherapy.
- Evaluation of treatment outcomes in indolent B cell lymphoma and acute myeloid leukemia (AML).
Main Results:
- Anti-CD20 chimeric antibody combined with CHOP therapy improved outcomes in indolent B cell lymphoma without increased toxicity.
- Multidrug resistance modifiers (PSC833, MS209) with chemotherapy benefited poor-risk AML patients expressing P-glycoprotein.
- Fludarabine-based (FL, FLAG) therapies were effective in relapsed AML.
- Early chemotherapy with ATRA, plus maintenance, reduced relapse in acute promyelocytic leukemia.
Conclusions:
- Combination therapies offer significant therapeutic benefits for various hematological malignancies.
- Targeted approaches, including anti-CD20 antibodies and resistance modifiers, enhance treatment efficacy.
- Optimized chemotherapy and ATRA regimens can effectively reduce relapse rates.